Navigation Links
Micromet Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/4/2010

omet-inc.com/">www.micromet-inc.com.

About Blinatumomab

Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas. Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study. Blinatumomab was generally well-tolerated by patients in the Phase 2 study.  The most frequently reported grade 3/4 adverse event was lymphopenia.  All other adverse events were infrequent and transient in nature.  Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional mo
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
2. Micromet, Inc. Reports Second Quarter 2009 Financial Results
3. Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
4. Micromet, Inc. Reports First Quarter 2009 Financial Results
5. Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
6. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
7. Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
8. Micromet, Inc. Reports Second Quarter 2008 Financial Results
9. Micromet, Inc. Reports First Quarter 2008 Financial Results
10. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
11. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 30, 2015 , ... Healthy and productive interpersonal relationships between ... According to Dr. Theo Wubbels (Professor of Education, Admissions Dean, Utrecht University), “Leadership ... “all kinds of behavior when the situation asks for it.” Wubbels, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Medflow, the leader in ... electronic health records system from the company exclusively dedicated to helping eye care ... an intuitive state-of-the-art solution combining modern cloud technology with Medflow’s proven expertise in ...
(Date:6/30/2015)... ... ... This Fourth of July, Peacock Alley celebrates the American ideals ... perseverance, commitment to quality, honesty and love of friends and family. These are the ... love of quilts, Peacock Alley was fully realized and grown while raising her family. ...
(Date:6/30/2015)... ... , ... Curly Hair Solutions™ is honoured to attend Cosmoprof North America in ... products from all over the world. For the first time ever, Curly Hair Solutions™ ... styling products focused entirely on meeting the needs of all curl types ...
(Date:6/29/2015)... ... June 30, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting more than 700,000 members and over 200 ...
Breaking Medicine News(10 mins):Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:National Association of Professional Women Inducts Melanie Richards, DMD, of Powdersville Pediatric Dentistry, Into its VIP Woman of the Year Circle 2
... after four private companies took over the reins of the ... created huge problems for patients for whom oxygen supply can ... that about 60,000 people are in need of oxygen at ... deliveries of Oxygen have taken a beating. A woman reportedly ...
... pediatrics at the Medical College of Wisconsin said that adult ... ,Both have different levels of chemicals (enzymes) in their ... in concentration with age. ,Hence this study suggests ... the young. ,This plays a vital role because ...
... online in the International Journal of Cancer on February 17, ... colon cancer and the level of physical activity in women. ... found no such link. ,Experts felt that since ... insulin besides increasing the gastrointestinal transit time, it might also ...
... claimed the lives of at least 52 inhabitants of ... French National Health Agency (INVS). // ,The incurable ... people since the epidemic broke out in the Indian ... have contracted the disease over the past week, according ...
... Parents need to be more watchful when taking care of their ... revealed that they are more likely to suffer from burn injuries ... ,Researchers at Malmo University in Sweden looked at 148 children up ... Hospital and 21 health centres. They discovered that 96 percent of ...
... Birth under the Guangdong Family Planning Research Institute in ... discovered 39 cases of new abnormal chromosomes. // ... scientists for genetic and cloning researches. ,Director ... these cases of abnormal chromosomes have been verified by ...
Cached Medicine News:Health News:Women, Exercise and Colon Cancer 2
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... IQmark family elevates your ECG and Spirometry capabilities ... and efficient patient care. The IQmark Diagnostic PDA ... clinics and medical centers as well as for ... conjunction with the IQmark Digital ECG PDA and ...
Medicine Products: